ImmuneRegen Releases Results from UMDNJ Study Confirming Homspera’s
Adult Stem Cell Activity
Tests on Human Bone Marrow by World Leader in Stem Cell Research
Show Boost in Production of Blood Cell Precursors
SCOTTSDALE, Ariz. (Business Wire EON/PRWEB ) April 16, 2008 --
ImmuneRegen®
BioSciences, Inc., a wholly owned biotechnology product development
and licensing subsidiary of IR
BioSciences Holdings, Inc. (OTCBB:IRBO), today announced the results
of a bone marrow study involving Homspera. Results point to the ability
of Homspera to
enhance formation of early-stage blood cells from adult hematopoietic
(blood-forming) stem cells. The studies, performed by University
of Medicine and Dentistry of New Jersey (UMDNJ) Professor
Pranela Rameshwar, Ph.D, not only were consistent with previous stem
cell study results, but also demonstrated the potency of Homspera.
The eminent stem cell
researcher compared Homspera to Substance
P, a peptide found naturally in the body, which is a known stimulant
of hematopoiesis. The data indicated Homspera was more effective than
Substance P at stimulating hematopoiesis. This impact on the production
of blood cells suggests the possibility that Homspera may have clinical
application in strengthening the human immune system.
The UMDNJ confirmatory study demonstrated Homspera significantly
enhanced stem cell differentiation. More than doubling (130 percent) the
differentiation exhibited in control cultures, Homspera’s
activity was most prominent in the production of two types of white
blood cells - granulocytes and macrophages. In comparison, Substance P
increased activity over control cultures by only 50 percent, and
required dosing at a much higher concentration than did Homspera. This
finding is significant because granulocytes (specifically neutrophils)
comprise over 70 percent of the white blood cells in the body. Together
neutrophils and macrophages play an important role in responding to
infection and destroying invading microorganisms. Homspera
similarly outperformed Substance P in cultures of red blood cell
precursors and also early-stage platelets, providing additional support
for Homspera’s potential to enhance the immune
system.
“The stimulatory effect of Homspera on adult
hematopoiesis, especially the production of granulocyte/monocyte
precursors, opens up possibilities in treating conditions such as
neutropenia,” explained Rameshwar, who is an
internationally recognized hematology expert and is also a member of
ImmuneRegen’s scientific advisory board. “Neutropenia
is a side effect of several drugs, especially those used in
chemotherapy. The ability to promote development of early-stage
granulocytes offers the potential to help replenish the low neutrophil
levels in certain individuals.”
Rameshwar’s study used bone marrow collected
from multiple human donors to minimize the effect of donor variability.
Findings confirmed the hematopoietic impact of Homspera that was
previously reported in a pilot study conducted by HemoGenix,
a research laboratory specializing in stem cell applications.
Said Michael K.
Wilhelm, ImmuneRegen president and CEO, “This
in vitro data further supports findings we have seen in vivo for
Homspera given after radiation exposure, which indicated that Homspera
counteracted the resulting decrease in white blood cells. We believe the
effects we are seeing on blood-forming stem cells may have implications
for treating a multitude of conditions including neutropenia,
thrombocytopenia, and even auto immune diseases.”
About University of Medicine and Dentistry of New Jersey
The University of Medicine and Dentistry of New Jersey (UMDNJ), the
state's university of the health sciences, is dedicated to the pursuit
of excellence in: the undergraduate, graduate, postgraduate and
continuing education of health professionals and scientists; the conduct
of biomedical, psychosocial, clinical and public health research; health
promotion, disease prevention and the delivery of health care; and
service to our communities and the entire state. Providing educational,
research and service programs at campuses in Camden, New
Brunswick/Piscataway, Newark, Scotch Plains and Stratford, in
communities throughout the state, and nationally and internationally
through advanced communication and information technologies, UMDNJ seeks
to meet the needs of our diverse constituencies and improve the health
and quality of life of the citizens of New Jersey and society at large.
For more information, please visit www.umdnj.edu.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc., IRBO, is a development-stage biotechnology
company focused on the research, development and licensing of
Homspera(TM), an adult stem cell active compound that can potentially
regenerate and strengthen the immune system. To advance its mission, the
Scottsdale, Ariz.-based company has forged numerous study partnerships
with industry and academic leaders, including Celgene Cellular
Therapeutics, Lovelace Respiratory Research Institute, HemoGenix and
Virion Systems. For more information, please visit the company's website
at www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential for ImmuneRegen's drug candidates,
science and technology, and all other statements in this press release
other than historical facts, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Securities Litigation Reform Act of 1995. ImmuneRegen intends
that such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when expected,
if at all, and, together with the ImmuneRegen's business, are subject to
various risks and uncertainties. ImmuneRegen's actual results could
differ materially from expected results as a result of a number of
factors, including the fact that preliminary results involved only a
small number of test mice, the subsequent investigations were limited in
scope, the uncertainties inherent in research and development
collaborations, pre-clinical and clinical trials and product development
programs (including, but not limited to the fact that future results or
research and development efforts may prove less encouraging than current
results or cause side effects not observed in current pre-clinical
trials), the evaluation of potential opportunities, the level of
corporate expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic report
on Form 10-KSB for the twelve months ended December 31, 2007 as filed
with the Securities and Exchange Commission. There are no guarantees
that any of ImmuneRegen's proposed products will prove to be
commercially successful. ImmuneRegen undertakes no duty to update
forward-looking statements.
MULTIMEDIA GALLERY http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5659412
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1Mb3ZlLUhvcnItUGlnZy1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.